+115.6%
DT vs GSK
+61.1%
+54.5%
-61.8%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 10y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | +1.6% | -1.0% | +2.7% | +1.9% |
| 7D | -2.5% | -5.4% | +2.9% | -1.1% |
| 30D | +3.5% | -4.6% | +8.2% | +4.7% |
| 3M | +26.7% | -5.1% | +31.8% | +28.0% |
| 6M | +36.1% | -11.4% | +47.6% | +39.4% |
| YTD | +18.6% | +0.7% | +17.9% | +15.7% |
| 1Y | +7.9% | +23.0% | -15.1% | -2.6% |
| 3Y | +8.6% | +48.0% | -39.4% | -11.9% |
| 5Y | -26.7% | +48.2% | -74.9% | -42.4% |
| All | +115.6% | +61.1% | +54.5% | +46.1% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 10y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
10y analysis · Full analysis span regression · 6 months rolling